

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P33024	SERIAL NO. 10/509,078
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Ahmed et al.	
		FILING DATE September 27, 2004	GROUP 1624

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	7,098,233	8/26/06	Di Cesare et al.	514	415	
	6,403,808	6/11/02	Glennon et al.	548	491	
	7,084,169	8/1/06	Shu-Hai Zhao	514	418	
	6,548,504	4/15/03	Bromidge et al.	514	252.12	
	6,489,488	12/3/02	Glennon et al.	548	439	
	6,518,297	2/11/03	Glennon et al.	514	415	
	US20030144505A1	7/31/03	Bromidge et al.	544	59	
	US20010051719A1	12/13/01	Bromidge et al.	544	56	
	US20040132742A1	7/8/04	Bromidge et al.	514	255.03	
	US20040034036A1	2/19/04	Bromidge et al.	514	255.03	
	6,849,644	2/1/05	Bromidge et al.	514	307	
	US20050176705A1	8/11/05	Steven Mark Bromidge	514	232.5	
	US20050176759A1	8/11/05	Ahmed et al.	514	310	
	US20050090496A1	4/28/05	Ahmed et al.	514	248	
	US20050090485A1	4/28/05	Bromidge et al.	514	217.01	
	7,262,188	8/28/07	MacDonald et al.	514	218	
	US20070275979A1	11/29/07	MacDonald et al.	514	255.03	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 02/89811 A1	11/14/02	WO				
	WO 05/021530	3/10/05	WO				
	WO 06/038006	4/13/06	WO				
	WO 07/039238	4/12/07	WO				
	WO 07/39219	4/12/07	WO				
	WO 07/039220	4/12/07	WO				
	WO 99/42465	8/26/99	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Mitchell et al., <i>Pharmacol. & Therapeutics</i> , 108: 320-333 (2005).
	Chuang et al., <i>Alzheimer's & Dementia, The Journal of the Alzheimer's Association</i> , 2(3/Supp. 1): S631-S632 (2006).
	London Stock Exchange Announcement – GlaxoSmithKline (GSK) plc, Issued on Thursday, December 13, 2007, New York, New York.
	A Dose Ranging Study to Investigate the Efficacy and Safety of SB-742457 in Alzheimer's Disease. NCT ID NO: NCT00224497 (Verified 2007).
	SB-742457 and Donepezil in Alzheimer's Disease. NCT ID NO: NCT00348192 (2006).
	Garcia-Alloza et al. <i>Neuropsychopharmacology</i> , 29: 410-416 (2004).
	Davies et al., <i>Drugs of the Future</i> , 30(5): 479-495 (2005).

EXAMINER

/Emily Bernhardt/

DATE CONSIDERED

4/10/2008

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

n:\kls\cases\p33024\rc\pto_1449_form.doc

04/10/2008

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /E.B./

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTY. DOCKET NO. P33024	SERIAL NO. 10/509,078
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use several sheets if necessary)</i>		APPLICANT Ahmed et al.	
		FILING DATE September 27, 2004	GROUP 1624

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	7,087,750 B2	8/8/06	Caldirola et al.	540	575	
	6,316,450B1	11/13/01	Bromidge et al.	514	253.05	
	US2006287334A1	12/21/06	Johnson et al.	514	253.07	
	US2007027139A1	2/1/07	Johnson et al.	514	218	
	US2007032504A1	2/8/07	Asa Elisabeth Gladwin	514	253.07	
	US2007191345A1	8/16/07	Ahmed et al.	514	217.07	
	US2007249603A1	10/25/07	Johnson et al.	514	235.2	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation	
						Yes	No
	WO 2003020707A1	3/13/03	WO				
	WO 2004050085A1	6/17/04	WO				
	WO2001017963A2	3/15/01	WO				
	WO2001098279A2	12/27/01	WO				
	WO2003104193A1	12/18/03	WO				
	WO2004041792A1	5/21/04	WO				
	WO2004080969A1	9/23/04	WO				
	WO2004035047A1	4/29/04	WO				
	WO2003095434A1	11/20/03	WO				
	WO2004026830A1	4/1/04	WO				
	WO2004026831A1	4/1/04	WO				
	WO2003014097A1	2/20/03	WO				
	WO2004078176A1	9/16/04	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Boes et al. <i>Eur. J. Med. Chem.</i> , 36(2): 165-178 (2001).
	Hirst et al. <i>Mol. Pharmacol.</i> , 64: 1295-1308 (2003).
	Sleight et al. <i>Br. J. Pharmacol.</i> , 124(3): 556-562 (1998).
	Lindner et al. <i>J. Pharmacol. Exp. Ther.</i> , 307(2): 682-691 (2003).
	Riemer et al. <i>J. Med. Chem.</i> , 46(7): 1273-1276 (2003).
	Chang-Fong et al. <i>Bioorg. Med. Chem. Lett.</i> , 14(8): 1961-1964 (2004).
	Glennon et al. <i>J. Med. Chem.</i> , 43(5): 1011-1018 (2000).
	Russell et al., <i>J. Med. Chem.</i> , 44(23): 3881-3895 (2001).
	Pineiro-Nunez et al. 229 th ACS Natl. Mtg., March 13-17, San Diego, Abst. Medi 282 (2005).
	Stadler et al. 37 th IUPAC Cong. August 14-19, Berlin, Abst MM-7 (1999).
	Holenz et al. <i>J. Med. Chem.</i> , 48(6): 1781-1795 (2005).

EXAMINER /Emily Bernhardt/	DATE CONSIDERED 4/10/2008
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

n:\kls\cases\p33024\rcel\pto_1449_form.doc

04/10/2008

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. 2/E.B./